Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 178 WM epcoritamab trial in relapsed or refractory Waldenstrom's macroglobulinemia
2025-522295-91-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of epcoritamab in Waldenström macroglobulinemia (WM) (2 arms), sponsored by HOVON. Primary endpoints: Recommended phase II dose and Major response rate after 12 cycles. Planned start Jun 2026; status: authorised.
02
Drugs
epcoritamab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2025-522295-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522295-91-00.